Keiko Miyazaki1, Matthew R. Orton1,
James A. d'Arcy1, Val Lewington2, Martin O. Leach1,
David J. Collins1, Dow-Mu Koh3
1CR-UK and EPSRC Cancer Imaging Centre,
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey,
United Kingdom; 2Department of Nuclear Medicine, Royal Marsden NHS
Foundation Trust, Sutton, Surrey, United Kingdom; 3Department of
Radiology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Dynamic
contrast-enhanced (DCE-) MRI is a technique that enables non-invasive
interrogation of tissue microvascular environment. The role of quantitative
DCE-MRI parameters in the assessment and prediction of response in patients
with liver metastases to a targeted radionuclide therapy was investigated
using both model-free and model-dependent data analyses. Distribution volume
and IAUGC60 were found to be potential predictors of response. The number of
fitted voxels and the enhancing fraction were found to be most sensitive in
assessing treatment response. This study demonstrates the role of DCE-MRI as
a potential biomarker for predicting and assessing treatment response.